Axsome Therapeutics Inc
NASDAQ:AXSM

  • LAST PRICE
    74.5900
  • TODAY'S CHANGE (%)
    1.1600 (1.5797%)
  • Bid / Lots
    74.5800/ 2
  • Ask / Lots
    74.6500/ 4
  • Open / Previous Close
    74.3300 / 73.4300
  • Day Range
    73.1500
    75.7700
  • 52 Week Range
    55.0200
    98.4000
  • Volume
    530,102

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
AXSM
Axsome Therapeutics Inc
3.5B
-11.7x
---
MOR
MorphoSys AG
2.8B
-5.6x
---
ARWR
Arrowhead Pharmaceuticals Inc
2.9B
-5.8x
---
RARE
Ultragenyx Pharmaceutical Inc
3.3B
-5.1x
---
TGTX
TG Therapeutics Inc
2.5B
74.0x
---
TWST
Twist Bioscience Corp
2.4B
-13.0x
---
As of 2024-06-03

Company Information

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Contact Information

Headquarters
One World Trade Center, 22Nd FloorNEW YORK, NY, United States 10007
Phone
212-332-3241
Fax
212-320-0245

Executives

Chairman of the Board, Chief Executive Officer, Founder, Interim Principal Financial Officer
Herriot Tabuteau
Chief Financial Officer
Nick Pizzie
Chief Operating Officer
Mark Jacobson
Executive Vice President - Commercial and Business Development
Lori Englebert
General Counsel
Hunter Murdock

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$3.5B
Revenue (TTM)
$251.0M
Shares Outstanding
47.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.25
EPS
$-6.38
Book Value
$4.03
P/E Ratio
-11.7x
Price/Sales (TTM)
13.9
Price/Cash Flow (TTM)
---
Operating Margin
-116.61%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.